Abstract
Adaptive designs are commonly used in clinical and drug development studies for optimum utilization of available resources. In this article, we consider the problem of estimating the effect of the selected (better) treatment using a two‐stage adaptive design. Consider two treatments with their effectiveness characterized by two normal distributions having different unknown means and a common unknown variance. The treatment associated with the larger mean effect is labeled as the better treatment. In the first stage of the design, each of the two treatments is independently administered to different sets of subjects, and the treatment with the larger sample mean is chosen as the better treatment. In the second stage, the selected treatment is further administered to additional subjects. In this article, we deal with the problem of estimating the mean of the selected treatment using the above adaptive design. We derive the uniformly minimum variance conditionally unbiased estimator (UMVCUE) of the mean effect of the selected treatment when multiple observations are available in the second stage. We show that the maximum likelihood estimator (a weighted sample average based on the first and the second stage data) is minimax and admissible for estimating the mean effect of the selected treatment. We also propose some plug‐in estimators obtained by plugging in the pooled sample variance in place of the common variance , in some of the existing estimators where is known. The performances of various estimators of the mean effect of the selected treatment are compared via a simulation study. For the illustration purpose, we also provide a real‐data application.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.